Rifampin should not be used with SOF/VEL. Use of other potent P-gp and/or moderate-potent CYP inducers such as rifabutin, pheytoin, phenobarbital, rifapentine, etc with SOF/VEL is not recommended.
Sofosbuvir/velpatasvir vs rifampin, ethinylestradiol/norgestimate, or famotidine
^
Study Design
In a phase 1, multiple-dose, randomized, cross-over drug-drug interaction study with 24 healthy individuals, the pharmacokinetics (PK), safety, and tolerability of a once-daily regimen of sofosbuvir 400mg and velpatasvir 100mg (SOF/VEL) were evaluated when co-administered with rifampin 600mg twice-daily.
Study Results
Specific PK values were not reported. The results showed a statistically significant decrease in the AUC of SOF and VEL by 72% and 82%, respectively, when co-administered with a multiple dose regimen of rifampin. Cmax for SOF and VEL was also decreased by 77% and 71%, respectively. The effects on the PK of rifampin were not reported.
References
E Mogalian, G Shen, L Moorehead, et al. Drug-drug interaction profile of sofosbuvir/velpatasvir fixed-dose combination. Easl. Barcelona, Spain. ; 2016.
icon on your home screen.